Guide

Pharmaceutical GMP readiness in Japan

Japan's drug framework is set by the Pharmaceuticals and Medical Devices Act (PMD Act / Act No. 145, formerly PAL). MHLW issues policy and approvals; PMDA conducts scientific review and GMP inspections. Japan-GMP (the Ministerial Ordinance on GMP for Drugs and Quasi-drugs, MHLW Ord. 179/2004 as amended) is harmonized with PIC/S since Japan's PIC/S accession in 2014. Marketing requires a Marketing Authorization Holder (MAH) established in Japan; foreign manufacturers register as Accredited Foreign Manufacturers (AFM). This guide covers the Japan-specific layer over an ICH Q10 PQS.

Start free trial Free trial, no credit card, onboard in days, not months.

Regulator and legal basis

MHLW (Ministry of Health, Labour and Welfare) sets policy; PMDA (Pharmaceuticals and Medical Devices Agency) reviews approvals and inspects. Statutes: PMD Act + GMP Ordinance. Japan is a PIC/S member and ICH founding regulator; J-GMP aligns closely with EudraLex Vol 4 but uses Japan-specific terminology and documentation expectations.

MAH, AFM, and the three-officer model

Each marketed drug needs a Japanese MAH holding a Type 1/2 marketing business licence. Every MAH must appoint three statutory officers: a General Marketing Compliance Officer, a Quality Assurance Officer, and a Safety Management Officer — each personally accountable. Foreign manufacturing sites must be registered as AFMs before product approval; PMDA performs on-site or paper GMP inspections of AFMs.

Documentation, language, and translation

Master Files (MFs) can be filed by foreign manufacturers to protect proprietary content from the MAH while still supporting the dossier. Submissions are in Japanese; PMDA accepts English supporting data but key approval documents must be translated. SOPs at AFMs do not need to be in Japanese but key records reviewed at inspection are commonly translated for the inspector.

Inspection style and common findings

PMDA inspections are thorough and document-driven; expect detailed review of validation, change control, OOS handling, and supplier qualification. Findings are classified and reported in the inspection report; serious findings can delay approval. The EU–Japan MRA covers human medicines for routine GMP inspections; PMDA still inspects AFMs at approval time for new applications.

A 90–180 day Japan readiness path

Days 0–30: appoint MAH, register AFM, name the three statutory officers. Days 31–90: align documentation to J-GMP; prepare bilingual SOP summaries; ensure Annex 1 / Annex 11 / GAMP 5 alignment. Days 91–180: pre-inspection self-audit, then host PMDA inspection.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

MHLW (Japan)

MHLW — Ministry of Health, Labour and Welfare (厚生労働省, Kōsei-rōdō-shō) — is Japan's national government ministry responsible for health, social welfare, labour + pensions policy + the legal owner of marketing-authorisatio…

ICH Q10

The international model for a Pharmaceutical Quality System covering the entire product lifecycle from development to discontinuation.

EU Annex 11

European equivalent of 21 CFR Part 11 — rules for computerised systems in GMP.

GAMP 5

ISPE's risk-based framework for validating computerised systems in regulated industries.

ALCOA+

The nine-letter mnemonic regulators use to grade your data integrity — and what every Part 11 audit really tests.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Industries this hits hardest

Frequently asked

Can a foreign company act as its own MAH?

No — the MAH must be established in Japan with the three statutory officers. Foreign manufacturers typically partner with a local MAH or stand up a Japanese subsidiary.

Does the EU–Japan MRA waive PMDA inspection?

It covers routine surveillance GMP inspections for human medicines, reducing duplicate on-site visits between PMDA and EU authorities. New-product approval inspections are typically still performed by PMDA.

What is a Master File (MF) and when should we file one?

An MF is a confidential filing by an API or component manufacturer that supports the MAH's drug dossier without disclosing proprietary detail to the MAH. File an MF when the proprietary content (synthesis, source) must be protected while still supporting Japanese approval.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →